Zanidatamab is a Monoclonal Antibody owned by Zymeworks, and is involved in 15 clinical trials, of which 11 are ongoing, and 4 are planned.
Zanidatamab is a bi-specific monoclonal antibody exhibits therapeutic effect on HER2-expressing tumors through a combination of two therapeutic mechanisms. One is enhanced effector function-mediated cytotoxicity including ADCC, CDC and ADCP due to increased binding and receptor saturation of tumors with the drug candidate and the other is by enhancing the phagocytosis and presentation of tumor antigens, which is the major aspect that leads to increased immune targeting of the tumors.
The revenue for Zanidatamab is expected to reach a total of $4.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zanidatamab NPV Report.
Zanidatamab is originated and owned by Zymeworks.
Zanidatamab is under development for the treatment of HER2-expressing cancers such as salivary gland cancer, endometrial cancer, biliary tract cancer, fallopian tube cancer, cervical cancer, gall bladder cancer, cholangiocarcinoma, bile duct cancer (cholangiocarcinoma), metastatic breast cancer (HER2-positive and HR positive), metastatic ovarian cancer, non-small cell lung cancer, gastric and gastroesophageal junction carcinomas, gastroesophageal junction, adenocarcinoma of the gastroesophageal junction, esophageal adenocarcinomas and metastatic colorectal cancer. It is administered intravenously. ZW-25 is a humanized bi-specific monoclonal antibody targeting the extracellular domain of HER2. The drug candidate is based on Azymetric technology.
It was also under development for adnexal carcinoma of skin.
Zymeworks is a clinical stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company product pipeline includes the lead candidate Zanidatamab for the treatment of biliary tract cancers, breast cancer, gastroesophageal adenocarcinomas and colorectal cancer, Zanidatamab Zovodotin for HER2-expressing cancers, ZW191 – TOPO1i antibody drug conjugate for ovarian and gynecological cancers and ZW171 – 2+1 T-Cell for solid tumor. Zymeworks technology platform comprises Azymetric, Zymelink, Efect and Protect. It operates in the US and Canada. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
The company reported revenues of (US Dollars) US$26.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 31.5% over FY2020. The operating loss of the company was US$215.6 million in FY2021, compared to an operating loss of US$187.5 million in FY2020. The net loss of the company was US$211.8 million in FY2021, compared to a net loss of US$180.6 million in FY2020. The company reported revenues of US$2.6 million for the third quarter ended September 2022, a decrease of 51.7% over the previous quarter.
Quick View – Zanidatamab
|Highest Development Stage|